A Lack of Antinociceptive or Antiinflammatory Effect of Botulinum Toxin A in an Inflammatory Human Pain Model

Sycha, 2004, Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature., J Neurol, 251, I19, 10.1007/s00415-004-1106-8

Göbel, 2001, Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes., Pain, 91, 195, 10.1016/S0304-3959(01)00292-5

Brin, 1987, Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm., Mov Disord, 2, 237, 10.1002/mds.870020402

Rollnik, 2000, Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study., Headache, 40, 300, 10.1046/j.1526-4610.2000.00044.x

Schnider, 2002, Physical therapy and adjunctive botulinum toxin type A in the treatment of cervical headache: a double-blind, randomised, placebo-controlled study., J Headache Pain, 3, 93, 10.1007/s101940200024

Evers, 2002, Treatment of headache with botulinum toxin A: a review according to evidence-based medicine criteria., Cephalalgia, 22, 699, 10.1046/j.1468-2982.2002.00390.x

Schulte-Mattler, 2004, Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study., Pain, 109, 110, 10.1016/j.pain.2004.01.016

Blersch, 2002, Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study., J Neurol Sci, 205, 59, 10.1016/S0022-510X(02)00313-1

Krämer, 2003, Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin., J Neurol, 250, 188, 10.1007/s00415-003-0971-x

Voller, 2003, A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A., Neurology, 61, 940, 10.1212/01.WNL.0000086374.92906.6A

Cui, 2004, Subcutaneous administration of botulinum toxin A reduces formalin-induced pain., Pain, 107, 125, 10.1016/j.pain.2003.10.008

Purkiss, 1997, Capsaicin stimulates release of substance P from dorsal root ganglion neurons via two distinct mechanisms., Biochem Soc Trans, 25, 542S, 10.1042/bst025542s

Welch, 2000, Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins., Toxicon, 38, 245, 10.1016/S0041-0101(99)00153-1

Bickel, 1998, Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in mean., Pain, 76, 317, 10.1016/S0304-3959(98)00062-1

Sycha, 2003, A simple pain model for the evaluation of analgesic effects of NSAIDs in healthy subjects., Br J Clin Pharmacol, 56, 165, 10.1046/j.0306-5251.2003.01869.x

Gustorff, 2004, The effects of remifentanil and gabapentin on hyperalgesia in a new extended inflammatory skin pain model in healthy volunteers., Anesth Analg, 98, 401, 10.1213/01.ANE.0000095150.76735.5D

Sycha, 2005, Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model., Pain, 113, 316, 10.1016/j.pain.2004.11.002

Gustorff, 2004, The sunburn pain model: the stability of primary and secondary hyperalgesia over 10 hours in a crossover setting., Anesth Analg, 98, 173, 10.1213/01.ANE.0000093224.77281.A5

Yarnitsky, 1995, Heat pain thresholds: normative data and repeatability., Pain, 60, 329, 10.1016/0304-3959(94)00132-X

Ziegler, 1999, Secondary hyperalgesia to punctate mechanical stimuli: central sensitization to A-fibre nociceptor input., Brain, 122, 2245, 10.1093/brain/122.12.2245

Baumgartner, 2002, Neurogenic hyperalgesia versus painful hypoalgesia: two distinct mechanisms of neuropathic pain., Pain, 96, 141, 10.1016/S0304-3959(01)00438-9

Minor, 1927, Ein neues verfahren zur klinischen untersuchung der schweissabsonderung., Z Neurol, 101, 302

Mahant, 2000, The current use of botulinum toxin., J Clin Neurosci, 7, 389, 10.1054/jocn.2000.0684

McMahon, 1992, Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: clues to the locus of action., J Biol Chem, 267, 21338, 10.1016/S0021-9258(19)36614-1

Carlton, 2001, Peripheral excitatory amino acids., Curr Opin Pharmacol, 1, 52, 10.1016/S1471-4892(01)00002-9

Chizh, 2002, Novel approaches to targeting glutamate receptors for the treatment of chronic pain: review article., Amino Acids, 23, 169, 10.1007/s00726-001-0124-4

De Biasi, 1988, Glutamate and substance P coexist in primary afferent terminals in the superficial laminae of spinal cord., Proc Natl Acad Sci U S A, 85, 7820, 10.1073/pnas.85.20.7820

Willis, 1991, Sensory mechanisms of the spinal cord., 10.1007/978-1-4899-0597-0

Schmelz, 1997, Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis., Neurosci Lett, 230, 117, 10.1016/S0304-3940(97)00494-1

Sauerstein, 2000, Electrically evoked neuropeptide release and neurogenic inflammation differ between rat and human skin., J Physiol, 529, 803, 10.1111/j.1469-7793.2000.00803.x

LaMotte, 1991, Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms., J Neurophysiol, 66, 190, 10.1152/jn.1991.66.1.190

Weidner, 2000, Acute effects of substance P and calcitonin gene-related peptide in human skin: a microdialysis study., J Invest Dermatol, 115, 1015, 10.1046/j.1523-1747.2000.00142.x

Hill, 2000, NK1 (substance P) receptor antagonists: why are they not analgesic in humans?, Trends Pharmacol Sci, 21, 244, 10.1016/S0165-6147(00)01502-9

Koppert, 1999, The effects of intradermal fentanyl and ketamine on capsaicin-induced secondary hyperalgesia and flare reaction., Anesth Analg, 89, 1521, 10.1213/00000539-199912000-00039

Hsu, 2004, Effect of volume and concentration on the diffusion of botulinum exotoxin A., Arch Dermatol, 140, 1351, 10.1001/archderm.140.11.1351